Avitar, Inc. (AVTI) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAvitar, Inc. (AVTI) trades at $0.00001. Avitar, Inc. operates as a holding company, focusing on the design, development, manufacture, and marketing of diagnostic test products and proprietary hydrophilic polyurethane foam disposables. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for AVTI: AVTI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Avitar, Inc. (AVTI) Healthcare & Pipeline Overview
Avitar, Inc. is a holding company specializing in diagnostic testing and medical disposables, offering onsite drug detection systems and hydrophilic polyurethane foam products. Targeting medical, diagnostic, dental, and consumer sectors, the company utilizes direct sales and strategic partnerships for distribution within the United States.
What Is the Investment Thesis for AVTI?
Avitar, Inc. presents a speculative investment opportunity within the medical devices and diagnostics sector. With a negative P/E ratio and a negative profit margin of -72.7%, the company's financial performance raises concerns about its profitability and sustainability. The company's gross margin stands at 26.9%. Growth catalysts include potential expansion of its ORALscreen product line into new markets and increased adoption of its wound care products. However, the company's small market capitalization and OTC listing introduce significant risks related to liquidity and regulatory compliance. The company's high beta of -51.52 suggests high volatility relative to the market. Investors should carefully consider these factors and conduct thorough due diligence before investing.
Based on FMP financials and quantitative analysis
AVTI Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited financial resources.
- Negative P/E ratio suggests the company is currently not profitable.
- Profit margin of -72.7% highlights significant challenges in achieving profitability.
- Gross margin of 26.9% indicates the company's ability to generate revenue after covering the cost of goods sold.
- Beta of -51.52 suggests the stock price moves inversely to the market.
Who Are AVTI's Competitors?
AVTI is benchmarked below against 3 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ITOC iTonic Holdings Ltd. | $2.53 | -9.64% | $17.4M | 30 5-pillar |
| QTEX Inspira Technologies Oxy B.H.N. Ltd. | $1.29 | -7.19% | $60.6M | 46 5-pillar |
| SI SHOULDER INNOVATIONS, INC. | $19.38 | -1.42% | $403M | 33 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AVTI's Key Strengths?
Proprietary technology in hydrophilic polyurethane foam.
- Established presence in the drug detection market with ORALscreen.
- Specialized wound care products addressing specific medical needs.
- Direct sales force and strategic partnerships for distribution.
What Are AVTI's Weaknesses?
Negative profitability and low market capitalization.
- Limited financial resources for research and development.
- Dependence on a small number of products and markets.
- OTC listing introduces liquidity and regulatory risks.
What Are the Key Risks for AVTI?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from larger companies in the medical devices and diagnostics industry.
- Regulatory changes affecting drug testing and medical device approvals.
- Negative profitability and low market capitalization.
- OTC listing introduces liquidity and regulatory risks.
- Product liability claims and recalls.
What Are AVTI's Competitive Advantages?
- Proprietary hydrophilic polyurethane foam technology.
- Established relationships with strategic partners and distributors.
- Specialized product offerings in niche markets (e.g., Illizarov Dressing).
- Brand recognition for ORALscreen drug detection systems.
What Does AVTI Do?
Founded in 1986 and based in Canton, Massachusetts, Avitar, Inc. functions as a holding company with a focus on the healthcare and diagnostics industries. The company, through its subsidiaries, designs, develops, manufactures, and markets a range of diagnostic test products and proprietary hydrophilic polyurethane foam disposables. These products cater to medical, diagnostics, dental, and consumer applications within the United States. Avitar's offerings include ORALscreen 4 and ORALscreen DRUGOMETER, oral fluid-based onsite assay systems designed for the detection of drugs of abuse, such as opiates, cocaine, marijuana, and methamphetamines. Additionally, the company provides medical-grade hydrophilic polyurethane foam disposables, including wound dressings like Hydrasorb, and custom foam products such as sinus dressings and devices used by astronauts for ear pressure relief. Avitar also develops specialty wound dressings for the cardiac catheter lab market and the Illizarov Dressing for orthopedic procedures. The company markets its products through a direct sales force, strategic partners, and a network of distributors, targeting employers, diagnostic test distributors, medical supply companies, governmental agencies, schools, and corporations.
What Products and Services Does AVTI Offer?
- Designs, develops, manufactures, and markets diagnostic test products.
- Offers oral fluid-based onsite assay systems for detecting drugs of abuse (ORALscreen 4 and ORALscreen DRUGOMETER).
- Provides medical-grade hydrophilic polyurethane foam disposables, including wound dressings (Hydrasorb).
- Develops custom foam products for medical and consumer applications.
- Creates specialty wound dressings for the cardiac catheter lab market.
- Produces the Illizarov Dressing for dressing external bone fixators in orthopedic procedures.
How Does AVTI Make Money?
- Develops and manufactures diagnostic test products and medical disposables.
- Markets products to employers, diagnostic test distributors, medical supply companies, governmental agencies, schools, and corporations.
- Utilizes a direct sales force and strategic partners for distribution.
- Generates revenue through the sale of diagnostic tests and medical disposables.
What Industry Does AVTI Operate In?
Avitar, Inc. operates within the medical devices and diagnostics industry, a sector characterized by technological innovation and stringent regulatory oversight. The industry is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in diagnostic technologies. Competition is intense, with established players and emerging companies vying for market share. Avitar's focus on onsite drug detection and specialized wound care products positions it within niche segments of this broader market. The company's success depends on its ability to innovate, obtain regulatory approvals, and effectively market its products.
Who Are AVTI's Key Customers?
- Employers seeking drug testing solutions for workplace safety.
- Diagnostic test distributors supplying medical facilities and laboratories.
- Medical supply companies providing products to hospitals and clinics.
- Governmental agencies requiring drug testing and medical supplies.
- Schools and corporations implementing drug testing programs.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Avitar, Inc. operates in the Healthcare sector. It is headquartered in Canton, US. The company is led by CEO Cory H. Gelmon. AVTI has traded publicly since 1994.
Key Financial Metrics
Return on equity for Avitar, Inc. stands at 25.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.14 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Avitar, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
AVTI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
AVTI Latest News
No recent news available for AVTI.
AVTI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for AVTI.
Price Targets
Wall Street price target analysis for AVTI.
AVTI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for AVTI; grades run from A+ (80-100) to F (below 30).
Leadership: Cory H. Gelmon
Unknown
Information about Cory H. Without further information, it is not possible to provide details about his career history, education, or previous roles.
Track Record: Information about Cory H. Gelmon's track record is not available in the provided data. Without further information, it is not possible to provide details about key achievements, strategic decisions, or company milestones under his leadership.
AVTI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Avitar, Inc. may not meet the minimum financial standards or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to the potential for limited information and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price volatility.
- Higher risk of fraud and manipulation compared to listed exchanges.
- Limited regulatory oversight and investor protection.
- Potential delisting or trading suspension due to non-compliance.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Check for any history of fraud or regulatory violations.
- Consult with a financial advisor before investing.
- The company has been in operation since 1986.
- Avitar has a portfolio of diagnostic test products and medical disposables.
- The company markets its products through a direct sales force and strategic partners.
- Avitar has a physical headquarters in Canton, Massachusetts, and an additional office in Calgary, Canada.
- The company's products are used in medical, diagnostic, dental, and consumer applications.
Common Questions About AVTI (Healthcare)
What do analysts say about AVTI stock?
Given the company's OTC listing and limited financial information, analyst coverage is likely sparse. Key valuation metrics such as P/E ratio are currently negative, reflecting the company's lack of profitability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is limited due to the company's OTC listing and disclosure status.